Birgit Thelen-Coco
Investor Relations Kontakt bei SCT-Spinal Cord Therapeutics GmbH
Profil
Birgit Thelen-Coco is currently the Head of Communications at SCT-Spinal Cord Therapeutics GmbH.
Aktive Positionen von Birgit Thelen-Coco
Unternehmen | Position | Beginn |
---|---|---|
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | Commercial Services |